Navigation Links
Potential Breakthrough Cancer Treatment Now Available From Vascular Designs
Date:9/2/2009

SAN JOSE, Calif., Sept. 2 /PRNewswire/ -- Vascular Designs, a medical device company, today announced that its IsoFlow(TM) infusion catheter has secured 510(k) marketing clearance by the U.S. Food and Drug Administration (FDA) for the direct delivery of medications into highly targeted areas. An important application of IsoFlow may be in the treatment of cancer.

(Photo:http://www.newscom.com/cgi-bin/prnh/20090902/SF69552)

The IsoFlow Infusion catheter enables sideways perfusion, which allows physicians to precisely target and isolate areas within the body where the infused drugs are delivered. With IsoFlow's unique design, medications can be delivered into areas that could not previously be treated directly, for instance, a cancerous tumor. According to numerous studies, this approach lets physicians increase drug concentrations at targeted sites while reducing systemic exposure, thereby improving efficacy and patient outcomes when treating illnesses such as cancer with chemotherapy.*

"In select clinical situations, the benefits of delivering a local endovascular drug dose without systemic exposure can reduce complications, improve results, and benefit patients," said Dr. Michael Dake, former chief of interventional radiology and current professor of cardiothoracic surgery at Stanford University School of Medicine. "The IsoFlow catheter facilitates the use of regional infusion therapies, especially in cases of challenging arterial anatomy where it helps achieve these promises of targeted delivery. IsoFlow is a valuable addition to our treatment arsenal."

IsoFlow is a dual balloon catheter designed to isolate a specific treatment region within the body from blood flow. It allows the infusion of fluids into the region and the perfusion of blood past the region to keep the blood flow intact during treatment. One of the many unique features of the IsoFlow infusion catheter is the ability to deliver medications sideways while using pressure to push the medication into the targeted area. The IsoFlow catheter is inserted over a guide wire for precise positioning within a patient's body. Once in place, medication is infused and isolated when both of the catheter's balloons are simultaneously inflated using fluid via a single inflation lumen. To view an animation detailing this process, please visit www.vasculardesigns.com.

"We are thrilled to receive FDA 510(k) marketing clearance after working on the IsoFlow catheter for more than seven years," said Robert Goldman, CEO and founder of Vascular Designs. "But what is most important is that individuals battling life-threatening illnesses will have a breakthrough treatment option to pursue with highly targeted drug delivery."

"IsoFlow could have a huge impact on the way many of today's deadliest illnesses such as cancer are treated. This method of local delivery may cause tumors that were previously unresponsive to systemic chemotherapy to respond. Additionally, the IsoFlow catheter may be able to provide treatment for a number of other medical conditions for which local delivery would be an ideal option," continued Goldman. "The potential applications of IsoFlow are exciting. We are looking forward to seeing how physicians will leverage this breakthrough catheter medical device into practice and the impact that it will surely make on the prognosis of so many patients."

The IsoFlow infusion catheter is now available. For more information on Vascular Designs or to purchase IsoFlow, please visit www.vasculardesigns.com or call (408) 484-9010.

About Vascular Designs

Vascular Designs, Inc. is a medical device company located in San Jose, California. Founder Robert Goldman developed the idea behind Vascular Designs and its innovative IsoFlow(TM) infusion catheter. His personal experience of watching loved ones suffer from and succumb to cancer had a profound influence on the creation of IsoFlow.

Vascular Designs has received FDA 510(k) marketing clearance for IsoFlow, which enables the direct delivery of medications into targeted areas. An important application for the IsoFlow catheter may be in the treatment of cancer. IsoFlow enables sideways perfusion, which allows physicians to precisely target and isolate areas within the body where the infused drugs are delivered. With the IsoFlow catheter's unique design, medications can be pushed into areas that could not previously be treated directly. According to numerous studies, this type of approach to delivery can increase drug concentrations at targeted sites while reducing systemic exposure, potentially improving treatment outcomes.

For more information on Vascular Designs or to purchase IsoFlow, please visit www.vasculardesigns.com or call (408) 484-9010.

* Chrysos, E., et al. Treatment of Unrescectable Malignant Abdominal, Pelvic and Thoracic Tumors Using Abdominal Pelvic and Thoracic Stop-flow Chemotherapy. Anticancer Research, Sept.-Oct. 2001. 21(5):3669-3675.

Collins, J.M., Pharmacologic Rationale for Regional Drug Delivery. Journal of Clinical Oncology, Vol. 2, 498-504. 1984.

Lygidakis, N.J., Sgourakis, G. and Aphinives, P. Upper Abdominal Stop-flow Perfusion as a Neo and Adjuvant Hypoxic Regional Chemotherapy for Resectable Gastric Carcinoma: A Prospective Randomized Clinical Trial. Hepatogastroenterology, May-Jun. 1999. 46(27): 2035-2038.

Miotto, D., et al. Hypoxic Antiblastic Stop-flow Perfusion: Clinical Outcome and Pharmacokinetic Findings. Journal of Chemotherapy, Nov. 16, 2004. Suppl. 5: 44-47.

Pilati, P., et al. Stop-flow Technique for Loco-regional Delivery of Antiblastic Agents: Literature Review and Personal Experience. European Journal of Surgical Oncology, Aug. 28, 2002. 544-553.

    Media Contact:
    The Hoffman Agency
    (408) 975-3002
    isoflow@hoffman.com

    Sales Contact:
    Vascular Designs
    (408) 484-9010
   http://www.vasculardesigns.com/V2/contact.html


'/>"/>
SOURCE Vascular Designs, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Sundia Receives the Highest Growth Potential Award from Zhangjiang
2. Heat forms potentially harmful substance in high-fructose corn syrup
3. A potential therapeutic agent for hepatic fibrosis
4. Herb Shows Potential for Rheumatoid Arthritis
5. Hissey Kientz, LLP Warns Duragesic Patch Users about Potential Health Risks of Fentanyl Overdose
6. ARKRAY Statement Regarding U.S. Food and Drug Administrations Public Health Notification: Potentially Fatal Errors With GDH-PQQ Glucose Monitoring Technology
7. Researchers identify potential new avenue to attack cancer
8. OcumatRx Announces Promising Clinical Trial Results for Implant with Potential to Permanently Treat Glaucoma
9. Frost & Sullivan: Outsourcing/Offshoring Environment Possesses Considerable Potential for Pharmacovigilance Market
10. Large Majority of Drivers 55 and Older Unaware of Potentially Dangerous Combination of Medications and Driving, Says New AAA Foundation Study
11. New class of compounds discovered for potential Alzheimers disease drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... 10, 2016 , ... Gout is like no other joint pain. It strikes ... with intense swelling and redness. It is triggered by the crystallization of uric acid ... the most susceptible, according to the February 2016 issue of Harvard Men's Health Watch. ...
(Date:2/10/2016)... ... 10, 2016 , ... AHRA: The Association for Medical Imaging ... Fox will serve as keynote speaker at the organization’s 2016 Spring Conference. Fox’s ... more effectively communicate with their own organizational staff and leadership. , “I ...
(Date:2/10/2016)... MN (PRWEB) , ... February 10, 2016 , ... ... that it will attend the Ohio Safety Congress and Expo event March 9-11, ... at the Greater Columbus Convention Center. , As the longest running and ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... revolutionary, biocompatible columns and accessories. These PEEK-lined stainless steel (PLS) columns combine the ... a solution that ensures the integrity of biological samples while operating at ultra-high ...
(Date:2/10/2016)... , ... February 10, 2016 , ... Workrite Ergonomics, who ... that has evolved from humble beginnings to being an internationally recognized leader in their ... we are today”, said Charlie Lawrence, President of Workrite. “Workrite recognized the importance ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... -- LexisNexis® Risk Solutions, a leading provider of data, ... LexisNexis Provider Performance Monitor , a clinical ... the quality and efficiency of provider networks through ... measuring provider performance through Provider Performance Monitor, payers ... improve the patient experience and reduce costs, as ...
(Date:2/10/2016)... 2016 Mast Therapeutics, Inc. (NYSE ... for sickle cell disease and heart failure, today announced ... units at a price to the public of $0.275 ... the Company,s common stock and one warrant to purchase ... exercise price of $0.42 per share. The warrants are ...
(Date:2/10/2016)... 10, 2016 ALSP, Inc. announced that it has ... for Medical Affairs in preparation for its move into clinical ... PhD, CEO, stated, "We are pleased to welcome Dallas ... working with an individual of such practical knowledge and far-reaching ... drawing deeply on his broad experience and success as a ...
Breaking Medicine Technology: